Table 2.
The perfused capillary length under baseline conditions (B) and percent changes at the end of reperfusion (R) in the experimental groups.
| Groups | Perfused capillary length (μm %) | Decrease R | |
|---|---|---|---|
| B | R | ||
| S | 9670 ± 115 | – | – |
| C | 9550 ± 135 | 3534 ± 41 | 63.0 ± 1.1a |
| P1a | 9850 ± 127 | 6895 ± 57 | 30.0 ± 1.4a,b |
| P1b | 9520 ± 147 | 7140 ± 92 | 25.0 ± 1.7a,b |
| P2a | 9700 ± 101 | 6208 ± 53 | 36.0 ± 0.9a,b |
| P2b | 9580 ± 119 | 6994 ± 80 | 27.0 ± 1.2a,b |
| P3 | 9720 ± 106 | 6027 ± 72 | 38.0 ± 1.1a,b |
| P4 | 9800 ± 110 | 4116 ± 65 | 58.0 ± 1.7a,b |
| P5 | 9680 ± 100 | 3388 ± 90 | 65.0 ± 1.4a,b |
S, sham-operated group; C, control group; P1a, hamsters treated with pLc intravenously infused, lower concentration; P1b, hamsters treated with pLc intravenously infused, higher concentration; P2a, animals treated with pLc topically applied, lower concentration and P2b, animals treated with pLc topically applied, higher concentration; P3, animals treated with topical application of L-NAME prior to pLc higher concentration; P4, hamsters treated with topical application of Apamin and Charybdotoxin prior to pLc higher concentration; P5, hamster treated with topical application of L-NAME plus Apamin and Charybdotoxin prior to pLc higher concentration. ap< 0.01 vs. baseline; bp < 0.01 vs. control group.